Catalyst Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview

Gyre Therapeutics

12/11/2021 17:43

* Catalyst Biosciences Inc  CBIO.OQ   CBIO.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 12. 
* The South San Francisco, California-based company is expected
to report  a 68.0% decrease in revenue to $650 thousand from
$2.03 million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Catalyst Biosciences
Inc is for a loss of 64 cents per share. For the same quarter
last year, the company reported a loss of 86 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $16​, about 81.6% above​ its last closing
price of $2.94. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.67       -0.66      -0.80     Missed  -21.2
 Jun. 30 2021  -0.70       -0.69      -0.64     Beat    7.9
 Mar. 31 2021  -0.57       -0.58      -0.79     Missed  -36.8​
 Dec. 31 2020  -0.95       -0.86      -0.86     Met     0.3
 ​​Sep.        -0.85       -0.81      -0.73     Beat    9.5
 30 2020                                                
 Jun. 30 2020  -0.77       -0.86      -0.96     Missed  -11.3​
 Mar. 31 2020  -0.39       -0.36      -0.28     Beat    23.3
 Dec. 31 2019  0.17        -0.31      -1.13     Missed  -258.7
 This summary was machine generated November 12 at 17:43 GMT. 
All figures in US dollars  unless otherwise stated